BioTelemetry, Inc. (BEAT): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAT Stock Price Chart Interactive Chart >
BEAT Price/Volume Stats
| Current price | $4.66 | 52-week high | $6.74 |
| Prev. close | $4.26 | 52-week low | $1.12 |
| Day low | $4.20 | Volume | 279,700 |
| Day high | $4.80 | Avg. volume | 1,209,200 |
| 50-day MA | $3.87 | Dividend yield | N/A |
| 200-day MA | $2.12 | Market Cap | 37.30M |
BioTelemetry, Inc. (BEAT) Company Bio
BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.
Latest BEAT News From Around the Web
Below are the latest news stories about HEARTBEAM INC that investors may wish to consider to help them evaluate BEAT as an investment opportunity.
HeartBeam Bags New Patent for Heart Attack DetectionCardiac technology provider HeartBeam (NASDAQ:BEAT) has bagged a patent to detect heart attacks with its smartwatch-based monitor in the U.S. The development further builds up on BEAT’s 3D-vector electrocardiogram (VECG) platform and allows the company to make headways into the ischemia and Arrhythmia detection product lines BEAT estimates that the global wearables medical device market will reach $196 billion by 2030 and the new patent further enhances its capabilities. At the same time, the company is also focusing on furthering its HeartBeam AIMI and HeartBeam AIMIGo systems as well. Shares of the company have climbed nearly 170% over the past six months. |
HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart AttacksHeartBeam Inc (NASDAQ: BEAT) announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office (USPTO). The company says that currently available wearables cannot provide a 12-lead ECG for heart attack detection, complex arrhythmia monitoring, or other cardiac disorders. HeartBeam's latest patent further expands on the company's anytime, anywhere ca |
New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac ArrhythmiasSANTA CLARA, Calif., November 16, 2022--New HeartBeam Patent for 12-Lead Electrocardiogram Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias |
HeartBeam Reports Third Quarter 2022 Financial ResultsSANTA CLARA, Calif., November 10, 2022--HeartBeam Reports Third Quarter 2022 Financial Results, Management to Host Webcast and Conference Call Today At 4:30 p.m. ET |
HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern TimeSANTA CLARA, Calif., October 25, 2022--HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time |
BEAT Price Returns
| 1-mo | 31.27% |
| 3-mo | 294.92% |
| 6-mo | 210.67% |
| 1-year | 8.37% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 51.30% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching BEAT
Want to do more research on Biotelemetry Inc's stock and its price? Try the links below:Biotelemetry Inc (BEAT) Stock Price | Nasdaq
Biotelemetry Inc (BEAT) Stock Quote, History and News - Yahoo Finance
Biotelemetry Inc (BEAT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...